NEW YORK (GenomeWeb News) – Agendia said today it has raised $65 million in a private round of equity financing.
The funds will be used to further expand the company's Symphony suite of breast cancer tests and the continued development of "our personalized medicine pipeline," Agendia CEO David Macdonald said in a statement. The company recently launched its Symphony suite in a formalin-fixed, paraffin-embedded format, and will soon launch its ColoPrint recurrence test for stage II colon cancer prognosis and prediction, he added.
Debiopharm Group led the round. Current investors Van Herk Group, ING Corporate Investments, Breedinvest, and Gilde Healthcare also participated, and new investors included Korys and others.
Last June, the Amsterdam-based molecular diagnostics firm put on hold a planned initial public offering citing unfavorable market conditions, two weeks after filing for the IPO.